| abstract |
The present invention relates to an LFA-1 inhibitor comprising at least one selected from the group consisting of a polyamine of formula (I) and pharmaceutically acceptable salts thereof: NH 2 — (CH 2 ) m 1-(NH) p 1 — (CH 2) m2- (NH) p2- (CH 2) m3- (NH) p3- (CH 2) m4- (NH) p4- (CH 2) m5-NH 2 ... (1) ( wherein, m1 ~ M5 is at least two greater than 0, each independently an integer of 0-7, the sum of m1 + m2 + m3 + m4 + m5 is greater than or equal to 2 and less than 18, and p1, p2, p3 and p4 are at least one , Others are each independently 0 or 1.); A pharmaceutical composition comprising the inhibitor and a method for preventing and treating a disease are provided. |